Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial

Clin Cancer Res (2025)

https://doi.org/10.1158/1078-0432.CCR-24-2310

Published: 13 January 2025

View article titled, Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial

Includes: Supplementary data

Journal Articles

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao, Alexander I. Spira, Konstantinos Leventakos, Melissa L. Johnson, Sai-Hong Ignatius Ou, Gregory J. Riely, Kenna Anderes, Wenjing Yang, James G. Christensen, Pasi A. Jänne

Clin Cancer Res (2023) 29 (16): 3074–3080.

https://doi.org/10.1158/1078-0432.CCR-23-0795

Published: 15 August 2023

View article titled, Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Includes: Supplementary data

Journal Articles

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS^G12C-Mutant Non–Small Cell Lung Cancer

Joshua K. Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R. Strickland, Rebecca S. Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R. Digumarthy, Justin F. Gainor, Anant P. Rajan, Edwin Nieblas-Bedolla, Aaron C. Burns, Jill Hallin, Peter Olson, James G. Christensen, Sylvia C. Kurz, Priscilla K. Brastianos, Hiroaki Wakimoto

Clin Cancer Res (2022) 28 (15): 3318–3328.

https://doi.org/10.1158/1078-0432.CCR-22-0383

Published: 02 August 2022

View article titled, Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Clin Cancer Res (2017) 23 (21): 6661–6672.

https://doi.org/10.1158/1078-0432.CCR-17-1192

Published: 31 October 2017

View article titled, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Includes: Supplementary data

Journal Articles

Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Cathy C. Zhang, Adam Pavlicek, Qin Zhang, Maruja E. Lira, Cory L. Painter, Zhengming Yan, Xianxian Zheng, Nathan V. Lee, Mark Ozeck, Ming Qiu, Qing Zong, Patrick B. Lappin, Anthony Wong, Paul A. Rejto, Tod Smeal, James G. Christensen

Clin Cancer Res (2012) 18 (18): 5008–5019.

https://doi.org/10.1158/1078-0432.CCR-12-1379

Published: 16 September 2012

View article titled, Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Includes: Supplementary data

Journal Articles

[¹⁸F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

Cathy C. Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpit, Cory L. Painter, Qin Zhang, Patrick B. Lappin, Tim Nichols, Maruja E. Lira, Timothy Affolter, Neeta R. Fahey, Carleen Cullinane, Mary Spilker, Kenneth Zasadny, Peter O'Brien, Dana Buckman, Anthony Wong, James G. Christensen

Clin Cancer Res (2012) 18 (5): 1303–1312.

https://doi.org/10.1158/1078-0432.CCR-11-1433

Published: 01 March 2012

View article titled, [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

Includes: Supplementary data

Journal Articles

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann, James G. Christensen, Martin R. Weiser

Clin Cancer Res (2011) 17 (3): 472–482.

https://doi.org/10.1158/1078-0432.CCR-10-0568

Published: 01 February 2011

View article titled, HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

Journal Articles

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

Thomas Bachleitner-Hofmann, Mark Y. Sun, Chin-Tung Chen, David Liska, Zhaoshi Zeng, Agnes Viale, Adam B. Olshen, Martina Mittlboeck, James G. Christensen, Neal Rosen, David B. Solit, Martin R. Weiser

Clin Cancer Res (2011) 17 (1): 122–133.

https://doi.org/10.1158/1078-0432.CCR-10-0253

Published: 04 January 2011

View article titled, Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

Includes: Supplementary data

Journal Articles

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

Cathy C. Zhang, Zhengming Yan, Qin Zhang, Kyle Kuszpit, Kenneth Zasadny, Ming Qiu, Cory L. Painter, Anthony Wong, Eugenia Kraynov, Maria E. Arango, Pramod P. Mehta, Ian Popoff, Gerald F. Casperson, Gerrit Los, Steve Bender, Kenna Anderes, James G. Christensen, Todd VanArsdale

Clin Cancer Res (2010) 16 (21): 5177–5188.

https://doi.org/10.1158/1078-0432.CCR-10-1343

Published: 31 October 2010

View article titled, PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

Includes: Supplementary data

Journal Articles

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

Cathy Zhang, Zhengming Yan, Cory L. Painter, Qin Zhang, Enhong Chen, Maria E. Arango, Kyle Kuszpit, Kenneth Zasadny, Max Hallin, Jill Hallin, Anthony Wong, Dana Buckman, Guizhen Sun, Ming Qiu, Kenna Anderes, James G. Christensen

Clin Cancer Res (2009) 15 (14): 4630–4640.

https://doi.org/10.1158/1078-0432.CCR-08-3272

Published: 15 July 2009

View article titled, PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

Includes: Supplementary data

Journal Articles

An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors

Paolo Accornero, Giuseppe Lattanzio, Tony Mangano, Roberto Chiarle, Riccardo Taulli, Francesca Bersani, Paolo E. Forni, Silvia Miretti, Claudio Scuoppo, Walter Dastrù, James G. Christensen, Tiziana Crepaldi, Carola Ponzetto

Clin Cancer Res (2008) 14 (7): 2220–2226.

https://doi.org/10.1158/1078-0432.CCR-07-2064

Published: 01 April 2008

View article titled, An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors

Journal Articles

A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

Patrick C. Ma, Erik Schaefer, James G. Christensen, Ravi Salgia

Clin Cancer Res (2005) 11 (6): 2312–2319.

https://doi.org/10.1158/1078-0432.CCR-04-1708

Published: 23 March 2005

View article titled, A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

Journal Articles

A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells

Håkon Hov, Randi Utne Holt, Torstein Baade Rø, Unn-Merete Fagerli, Henrik Hjorth-Hansen, Vadim Baykov, James G. Christensen, Anders Waage, Anders Sundan, Magne Børset

Clin Cancer Res (2004) 10 (19): 6686–6694.

https://doi.org/10.1158/1078-0432.CCR-04-0874

Published: 08 October 2004

View article titled, A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells

Journal Articles

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship

Clin Cancer Res (2003) 9 (1): 327–337.

Published: 01 January 2003

View article titled, In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: <subtitle>Determination of a Pharmacokinetic/Pharmacodynamic Relationship</subtitle>

Journal Articles

High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo

James G. Christensen, Randall E. Schreck, Emily Chan, Xueyan Wang, Chris Yang, Luna Liu, Jean Cui, Li Sun, James Wei, Julie M. Cherrington, Dirk B. Mendel

Clin Cancer Res (2001) 7 (12): 4230–4238.

Published: 01 December 2001

View article titled, High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo

NARROW

Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS^G12C-Mutant Non–Small Cell Lung Cancer

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

[¹⁸F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors

A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship

High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only